Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-06-05
- Lead Sponsor
- Chongqing Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT00913315
- Locations
- 🇨🇳
Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Study of ONO-8539 in Patients With Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 435
- Registration Number
- NCT00876421
Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT00836381
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1355
- Registration Number
- NCT00802373
Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 374
- Registration Number
- NCT00795509
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00768521
Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2009-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT00746681
- Locations
- 🇬🇧
Pfizer Investigational Site, Plymouth, United Kingdom
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- KYU-SUNG LEE
- Target Recruit Count
- 173
- Registration Number
- NCT00730535
- Locations
- 🇰🇷
Samsung Medical Center, Irwon-dong, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 117
- Registration Number
- NCT00703703
- Locations
- 🇺🇸
Investigative Site, Morgantown, West Virginia, United States
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2792
- Registration Number
- NCT00688688
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.